CIK 0001628171
- Large accelerated filer
Revolution Medicines, Inc.
Sign in to watch- Ticker
- RVMD
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 472029180
- Phone
- +1 650-481-6801
- Business address
- 700 SAGINAW DR, REDWOOD CITY, CA, 94063
Securities
- RVMD Common Stock Nasdaq
- RVMDW Warrant Nasdaq
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $85,328,124
- in 21 filings, $85.3M under 10b5-1 plans
Net −$85,328,124. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-08-01 | GOLDSMITH MARK A See Remarks | Option exercise 10b5-1 | +10,000 | $4.09 | $41K | 321,885 |
| 2024-08-01 | GOLDSMITH MARK A See Remarks | Sale 10b5-1 | −6,783 | $45.60 | $309K | 315,102 |
| 2024-08-01 | GOLDSMITH MARK A See Remarks | Sale 10b5-1 | −3,217 | $46.48 | $150K | 311,885 |
| 2024-08-01 | GOLDSMITH MARK A See Remarks | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,000 | 281,229 | ||
| 2024-07-15 | Kelsey Stephen Michael See Remarks | Option exercise 10b5-1 | +16,667 | $4.09 | $68K | 285,740 |
| 2024-07-15 | Kelsey Stephen Michael See Remarks | Sale 10b5-1 | −1,100 | $43.99 | $48K | 284,640 |
| 2024-07-15 | Kelsey Stephen Michael See Remarks | Sale 10b5-1 | −2,128 | $44.94 | $96K | 282,512 |
| 2024-07-15 | Kelsey Stephen Michael See Remarks | Sale 10b5-1 | −5,760 | $46.08 | $265K | 276,752 |
| 2024-07-15 | Kelsey Stephen Michael See Remarks | Sale 10b5-1 | −3,800 | $47.02 | $179K | 272,952 |
| 2024-07-15 | Kelsey Stephen Michael See Remarks | Sale 10b5-1 | −3,879 | $48.06 | $186K | 269,073 |
| 2024-07-15 | Kelsey Stephen Michael See Remarks | Option exercise · Stock Option (Right to Buy) 10b5-1 | −16,667 | 73,332 | ||
| 2024-07-12 | GOLDSMITH MARK A See Remarks | Option exercise 10b5-1 | +25,000 | $4.09 | $102K | 336,885 |
| 2024-07-12 | GOLDSMITH MARK A See Remarks | Sale 10b5-1 | −25,000 | $45.05 | $1.1M | 311,885 |
| 2024-07-12 | GOLDSMITH MARK A See Remarks | Sale 10b5-1 | −5,000 | $45.01 | $225K | 25,424 |
| 2024-07-12 | GOLDSMITH MARK A See Remarks | Sale 10b5-1 | −5,000 | $45.01 | $225K | 25,424 |
| 2024-07-12 | GOLDSMITH MARK A See Remarks | Option exercise · Stock Option (Right to Buy) 10b5-1 | −25,000 | 291,229 | ||
| 2024-07-09 | Cislini Jeff General Counsel | Sale 10b5-1 | −2,399 | $40.83 | $98K | 47,088 |
| 2024-07-09 | Patel Sushil Director | Option exercise 10b5-1 | +2,155 | $16.80 | $36K | 22,103 |
| 2024-07-09 | Patel Sushil Director | Sale 10b5-1 | −2,155 | $44.00 | $95K | 19,948 |
| 2024-07-09 | Patel Sushil Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,155 | 32,490 |
Page 23 of 29 · 569 trades